Verastem (VSTM) Competitors $6.11 +0.03 (+0.49%) Closing price 02/13/2025 04:00 PM EasternExtended Trading$6.02 -0.09 (-1.39%) As of 02/13/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VSTM vs. EBS, RIGL, CDXS, IRWD, XOMA, VNDA, SGMO, LXRX, ACHV, and AGENShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Agenus (AGEN). These companies are all part of the "biotechnology" industry. Verastem vs. Emergent BioSolutions Rigel Pharmaceuticals Codexis Ironwood Pharmaceuticals XOMA Vanda Pharmaceuticals Sangamo Therapeutics Lexicon Pharmaceuticals Achieve Life Sciences Agenus Emergent BioSolutions (NYSE:EBS) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation. Is EBS or VSTM more profitable? Verastem has a net margin of 0.00% compared to Emergent BioSolutions' net margin of -18.55%. Emergent BioSolutions' return on equity of -9.91% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets Emergent BioSolutions-18.55% -9.91% -3.31% Verastem N/A -332.73%-73.97% Do analysts prefer EBS or VSTM? Emergent BioSolutions currently has a consensus price target of $14.33, suggesting a potential upside of 51.44%. Verastem has a consensus price target of $13.63, suggesting a potential upside of 123.00%. Given Verastem's higher possible upside, analysts plainly believe Verastem is more favorable than Emergent BioSolutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent BioSolutions 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Verastem 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EBS or VSTM? In the previous week, Emergent BioSolutions had 4 more articles in the media than Verastem. MarketBeat recorded 4 mentions for Emergent BioSolutions and 0 mentions for Verastem. Emergent BioSolutions' average media sentiment score of 0.66 beat Verastem's score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the media. Company Overall Sentiment Emergent BioSolutions Positive Verastem Neutral Does the MarketBeat Community believe in EBS or VSTM? Verastem received 188 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.72% of users gave Emergent BioSolutions an outperform vote while only 65.28% of users gave Verastem an outperform vote. CompanyUnderperformOutperformEmergent BioSolutionsOutperform Votes42566.72% Underperform Votes21233.28% VerastemOutperform Votes61365.28% Underperform Votes32634.72% Which has more risk & volatility, EBS or VSTM? Emergent BioSolutions has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Which has preferable earnings & valuation, EBS or VSTM? Verastem has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent BioSolutions$1.05B0.49-$760.50M-$4.10-2.31Verastem$2.60M104.60-$87.37M-$3.19-1.92 Do insiders & institutionals have more ownership in EBS or VSTM? 78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 2.2% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryVerastem beats Emergent BioSolutions on 10 of the 17 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$271.96M$6.93B$5.81B$9.15BDividend YieldN/A2.91%5.29%4.00%P/E Ratio-1.929.8526.0719.43Price / Sales104.60251.71446.4071.49Price / CashN/A75.4646.0938.87Price / Book2.695.577.415.07Net Income-$87.37M$123.72M$3.19B$222.90M7 Day Performance5.53%-0.11%0.92%1.23%1 Month Performance21.23%2.71%4.83%4.23%1 Year Performance-48.48%3.56%23.85%20.29% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem2.9854 of 5 stars$6.11+0.5%$13.63+123.0%-48.0%$271.96M$2.60M-1.9250EBSEmergent BioSolutions4.3293 of 5 stars$10.50-6.7%$14.33+36.5%+495.3%$568.78M$1.05B-2.561,600Gap DownRIGLRigel Pharmaceuticals3.2108 of 5 stars$21.16-2.3%$36.20+71.1%+86.3%$372.73M$157.47M151.15160Short Interest ↑Gap DownCDXSCodexis3.8614 of 5 stars$4.27+1.9%$8.33+95.2%+51.0%$347.49M$70.14M-4.91250News CoverageIRWDIronwood Pharmaceuticals4.3727 of 5 stars$2.10-10.3%$10.67+407.9%-86.8%$336.06M$442.73M-70.00220Upcoming EarningsInsider TradeShort Interest ↑XOMAXOMA4.544 of 5 stars$24.88-6.5%$72.00+189.4%+38.6%$293.09M$4.76M-7.1510Analyst UpgradeVNDAVanda Pharmaceuticals4.1261 of 5 stars$4.31-2.3%$15.50+259.6%+15.8%$251.32M$192.64M-15.39290Earnings ReportNews CoverageSGMOSangamo Therapeutics1.4878 of 5 stars$1.17-4.9%$5.17+341.6%+74.6%$244.12M$52.29M-1.56480Gap UpLXRXLexicon Pharmaceuticals1.6208 of 5 stars$0.73-3.8%$5.00+587.4%-74.7%$179.12M$1.20M-0.97140Gap UpACHVAchieve Life Sciences2.3867 of 5 stars$3.26-0.3%$14.80+354.0%-24.2%$112.11MN/A-2.8820Short Interest ↓Gap UpAGENAgenus3.8201 of 5 stars$3.51-7.6%$10.00+184.9%-77.0%$82.35M$156.31M-0.31440Gap Down Related Companies and Tools Related Companies Emergent BioSolutions Alternatives Rigel Pharmaceuticals Alternatives Codexis Alternatives Ironwood Pharmaceuticals Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Sangamo Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Achieve Life Sciences Alternatives Agenus Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VSTM) was last updated on 2/14/2025 by MarketBeat.com Staff From Our Partners*Breaking News!* This Pharma NASDAQ Company and the U.S Army!!! This Little Known NASDAQ Company just released positive results from its drugs that have been undergoing testi...Trading Wire | SponsoredJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | Sponsored[RFK Jr CONFIRMED] But Will THIS Be His DownfallRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s #1 investment during Trump’s termWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.